Navigation Links
Fertility drugs given 'all-clear' in new study

Concerns about the use of letrozole, an easy-to-use and inexpensive drug for the treatment of infertility, appear to be unfounded, according to a major study co–authored by Dr. Togas Tulandi, Director of Division of Reproductive Endocrinology and Infertility, McGill University Health Centre (MUHC) and Chief of Obstetrics and Gynecology at the Jewish General Hospital, and Professor of Obstetrics and Gynecology at McGill University. Their findings, which are currently available in an early online edition of Fertility and Sterility, showed that babies whose mothers were treated with letrozole had the same rate of birth defects as those whose mothers were treated with clomiphene citrate ?the low-risk, first-line treatment for infertility for more than 40 years.

"We found no statistically significant difference in the overall rates of major and minor malformations or chromosomal abnormalities between newborns in the two groups," says Dr. Tulandi. "Our findings indicate concerns about a link between letrozole and birth defects are unfounded. This is significant because it confirms that letrozole can indeed be used in the treatment of infertility without increasing risk to the fetus."

The study contradicts an earlier, much smaller study linking letrozole to increased rates of inherited malformations. This study led to widespread concern about the use of letrozole, a drug which has been widely used in the treatment of infertility in recent years.

"There were several methodological problems with the earlier study," says Dr. Tulandi. "For one thing, it compared the incidence of birth defects in children conceived spontaneously with that in children conceived through fertility treatments using letrozole. This is an apples-and-oranges comparison, because there are always fewer birth defects in children conceived spontaneously." The earlier study also compared different age groups between the control and treatment.

The new study by Dr. Tulandi, Dr
'"/>

Source:McGill University


Page: 1 2

Related biology news :

1. Fertility hope as study shows eggs survive in older ovaries
2. Molecular machine may lead to new drugs to combat human diseases
3. Researchers identify target for cancer drugs
4. MetaChip provides quick, efficient toxicity screening of potential drugs
5. Newly discovered pathway might help in design of cancer drugs
6. UNC launches study of liver injury caused by drugs
7. Findings have implications for tracking disease, drugs at the molecular level
8. Future diabetes drugs may target new protein interaction
9. UCLA study assesses cost-effectiveness of Hepatitis B drugs
10. Sponges as drugs
11. Newest HIV drugs should be used with FUZEON(R)
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Fertility drugs given all clear new study

Breaking Biology News(10 mins):Study reveals how Arctic food webs affect mercury in polar bears 2MSU researcher unveils new approach to treat lower back pain 2H1N1 influenza adopted novel strategy to move from birds to humans 2H1N1 influenza adopted novel strategy to move from birds to humans 3H1N1 influenza adopted novel strategy to move from birds to humans 4Reportlinker Adds H1N1 28Swine Influenza 29 Market Assessment 28Latest Data Company Profiles Implications for Immunoassays and Molecular Assays 29 58286 1Reportlinker Adds H1N1 28Swine Influenza 29 Market Assessment 28Latest Data Company Profiles Implications for Immunoassays and Molecular Assays 29 58286 2Reportlinker Adds H1N1 28Swine Influenza 29 Market Assessment 28Latest Data Company Profiles Implications for Immunoassays and Molecular Assays 29 58286 3Reportlinker Adds H1N1 28Swine Influenza 29 Market Assessment 28Latest Data Company Profiles Implications for Immunoassays and Molecular Assays 29 58286 4The MED Group Signs Preferred Supplier Agreement for Masimo SET 28R 29 Pulse Oximetry Solutions 58282 1The MED Group Signs Preferred Supplier Agreement for Masimo SET 28R 29 Pulse Oximetry Solutions 58282 2The MED Group Signs Preferred Supplier Agreement for Masimo SET 28R 29 Pulse Oximetry Solutions 58282 3The MED Group Signs Preferred Supplier Agreement for Masimo SET 28R 29 Pulse Oximetry Solutions 58282 4The MED Group Signs Preferred Supplier Agreement for Masimo SET 28R 29 Pulse Oximetry Solutions 58282 5Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 58278 1Mayo Clinic Offers Perspective on Health Care Reform in New England Journal of Medicine 58278 2